We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands (SWITCH)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01536626
First Posted: February 22, 2012
Last Update Posted: February 24, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Novo Nordisk A/S
February 16, 2012
February 22, 2012
February 24, 2017
June 9, 2006
April 10, 2007   (Final data collection date for primary outcome measure)
HbA1c (glycosylated haemoglobin)
Same as current
Complete list of historical versions of study NCT01536626 on ClinicalTrials.gov Archive Site
  • Number of hypoglycaemic events
  • Treatment satisfaction: ITSQ (Insulin Treatment Satisfaction Questionnaire)
  • Quality of Life (QoL) using the World Health Organization Wellbeing Index (WHO-5)
Same as current
Not Provided
Not Provided
 
Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands
SWITCH Mixtard® 30 NovoLet® to NovoMix® 30 FlexPen®. An Observational Study
This study is conducted in Europe. The aim of this observational study is to observe and investigate the process of switching from premixed human insulin 30/70 (BHI 30) to biphasic insulin aspart 30/70 (BIAsp 30) in an outpatient setting.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients with type 2 diabetes treated with BHI 30 who have been by the physician for some reason switched to BIAsp 30
  • Diabetes
  • Diabetes Mellitus, Type 2
Drug: biphasic insulin aspart 30
Prescription at the discretion of the treating physician
BIAsp 30 users
Intervention: Drug: biphasic insulin aspart 30
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
211
April 10, 2007
April 10, 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Type 2 diabetic subjects treated with BHI 30
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
 
NCT01536626
BIASP-1925
No
Not Provided
Not Provided
Novo Nordisk A/S
Novo Nordisk A/S
Not Provided
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
Novo Nordisk A/S
February 2017